These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36198438)

  • 1. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
    Hoisnard L; Pina Vegas L; Dray-Spira R; Weill A; Zureik M; Sbidian E
    Ann Rheum Dis; 2023 Feb; 82(2):182-188. PubMed ID: 36198438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.
    Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH
    Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
    Molander V; Bower H; Frisell T; Delcoigne B; Di Giuseppe D; Askling J;
    Ann Rheum Dis; 2023 Feb; 82(2):189-197. PubMed ID: 36150749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK-inhibitors and risk on serious viral infection, venous thromboembolism and cardiac events in patients with rheumatoid arthritis: A protocol for a prevalent new-user cohort study using the Danish nationwide DANBIO register.
    Faquetti ML; Vallejo-Yagüe E; Cordtz R; Dreyer L; Burden AM
    PLoS One; 2023; 18(7):e0288757. PubMed ID: 37498856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case-time control study and a nested case-control study based on the French national health insurance (SNDS) cohort.
    Berthe P; Scailteux LM; Lescoat A; Staumont D; Coiffier G; Guéret P; Dupuy A; Oger E; Droitcourt C
    BMJ Open; 2022 Sep; 12(9):e059979. PubMed ID: 36130766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
    Pappas DA; O'Brien J; Guo L; Shan Y; Baker JF; Kricorian G; Stryker S; Collier DH
    Arthritis Res Ther; 2023 Sep; 25(1):166. PubMed ID: 37689684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Janus Kinase inhibitors in rheumatoid arthritis treatment.
    Reddy V; Cohen S
    Curr Opin Rheumatol; 2021 May; 33(3):300-306. PubMed ID: 33767091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
    Desai RJ; Pawar A; Weinblatt ME; Kim SC
    Arthritis Rheumatol; 2019 Jun; 71(6):892-900. PubMed ID: 30552833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase inhibitors: efficacy and safety.
    Cohen S; Reddy V
    Curr Opin Rheumatol; 2023 Nov; 35(6):429-434. PubMed ID: 37682051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
    Fitton J; Melville AR; Emery P; Nam JL; Buch MH
    Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.
    Xie W; Huang Y; Xiao S; Sun X; Fan Y; Zhang Z
    Ann Rheum Dis; 2019 Aug; 78(8):1048-1054. PubMed ID: 31088790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
    Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
    Atzeni F; Popa CD; Nucera V; Nurmohamed MT
    Expert Rev Clin Immunol; 2022 Mar; 18(3):233-244. PubMed ID: 35129033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study.
    Song YJ; Cho SK; Kim JY; You SH; Kim H; Jung SY; Sung YK
    Semin Arthritis Rheum; 2023 Aug; 61():152214. PubMed ID: 37172496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
    Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
    Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
    Mori S; Ogata F; Tsunoda R
    Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
    Misra DP; Pande G; Agarwal V
    Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
    Cohen SB; van Vollenhoven RF; Winthrop KL; Zerbini CAF; Tanaka Y; Bessette L; Zhang Y; Khan N; Hendrickson B; Enejosa JV; Burmester GR
    Ann Rheum Dis; 2021 Mar; 80(3):304-311. PubMed ID: 33115760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
    Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
    Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.